Current management and novel agents for malignant melanoma

Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byung, Mukhi, Nikhil, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293076/
https://www.ncbi.nlm.nih.gov/pubmed/22333219
http://dx.doi.org/10.1186/1756-8722-5-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293076/
https://www.ncbi.nlm.nih.gov/pubmed/22333219
http://dx.doi.org/10.1186/1756-8722-5-3

Ejemplares similares